Probiotics and Their Derivatives as Treatments for Inflammatory Bowel Disease

被引:48
|
作者
Prisciandaro, Luca [1 ,2 ,3 ]
Geier, Mark [4 ]
Butler, Ross [1 ,2 ]
Cummins, Adrian [3 ]
Howarth, Gordon [1 ,2 ]
机构
[1] Sch Agr Food & Wine, Discipline Agr & Anim Sci, Adelaide, SA, Australia
[2] Ctr Paediat & Adolescent Gastroenterol, Adelaide, SA, Australia
[3] Queen Elizabeth Hosp, Dept Gastroenterol & Hepatol, Adelaide, SA, Australia
[4] S Australian Res & Dev Inst, PPPI Nutr Res Lab, Roseworthy, SA, Australia
关键词
inactivated bacteria; inflammatory bowel disease; probiotics; supernatants; LACTOBACILLUS-FERMENTUM; ULCERATIVE-COLITIS; MODEL; STRAIN; LACTIS; MURINE; CELLS; SUPERNATANT; PREBIOTICS; DEAD;
D O I
10.1002/ibd.20938
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Inflammatory bowel disease (IBD) is a chronic relapsing disorder that is increasing in prevalence in Western society and has been linked to the development of colorectal cancer. There remains no definitive treatment for IBD, hence recent investigations have focused on the development of new therapeutics, including probiotics, which can reduce intestinal inflammation and restore balance to the gastrointestinal microbiota. Probiotics are currently being studied in greater detail, albeit predominantly in animal models of IBD. Clinical studies have yielded promising findings and justify further investigation. Furthermore, the use of inactivated probiotics as well as the soluble products produced by these bacteria has demonstrated therapeutic potential, and may in fact be more suitable, as there is no risk of sepsis associated with their administration and they can be manufactured with greater quality control. Further research is essential to define the mechanism and source of probiotic action, and to identify more efficacious strains, while future clinical trials must focus on determining whether the bacterial and genetic profiles of IBD patients influence the effectiveness of treatment.
引用
收藏
页码:1906 / 1914
页数:9
相关论文
共 50 条
  • [41] Emerging treatments for inflammatory bowel disease
    Hazel, Karl
    O'Connor, Anthony
    [J]. THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2020, 11
  • [42] Pharmacogenetics of treatments for inflammatory bowel disease
    Lucafo, Marianna
    Franca, Raffaella
    Selvestrel, Davide
    Curci, Debora
    Pugnetti, Letizia
    Decorti, Giuliana
    Stocco, Gabriele
    [J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2018, 14 (12) : 1209 - 1223
  • [43] New treatments for inflammatory bowel disease
    David S. Rampton and D.Phil
    [J]. World Journal of Gastroenterology, 1998, (05) : 6 - 13
  • [44] Nutritional treatments in inflammatory bowel disease
    Maria O’Sullivan
    Colm O’Morain
    [J]. Current Treatment Options in Gastroenterology, 2001, 4 (3) : 207 - 213
  • [45] Novel treatments for inflammatory bowel disease
    Lee, Hyo Sun
    Park, Soo-Kyung
    Park, Dong Il
    [J]. KOREAN JOURNAL OF INTERNAL MEDICINE, 2018, 33 (01): : 20 - 27
  • [46] Novel treatments in inflammatory bowel disease
    Pathmakanthan, S
    Stack, WA
    [J]. HOSPITAL MEDICINE, 1999, 60 (01): : 19 - 23
  • [47] Unconventional treatments for inflammatory bowel disease
    Guslandi, M
    [J]. CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1998, 59 (08): : 530 - 536
  • [48] Newer treatments for inflammatory bowel disease
    Stotland, BR
    Lichtenstein, GR
    [J]. DRUGS OF TODAY, 1998, 34 (02): : 177 - 192
  • [49] New treatments for inflammatory bowel disease
    Rampton, DS
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 1998, 4 (05) : 369 - 376
  • [50] Probiotics and prebiotics in inflammatory bowel disease: microflora 'on the scope'
    Damaskos, Dimitrios
    Kolios, George
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 65 (04) : 453 - 467